ALLMedicine™ Epistaxis Center

Jun 28th, 2022 - To discuss the clinical features of a patient with hereditary hemorrhagic telangiectasia (HHT). The clinical data of one patient with HHT are retrospectively analysed. In addition, we review the relevant literature. A 32-year-old male patient was ...

Jun 26th, 2022 - To determine the effectiveness of intranasal topical application of tranexamic acid in reducing the need for anterior nasal packing and determine the number of episodes of rebleeding in adult patients presenting with spontaneous atraumatic anterio...

Jun 25th, 2022 - Hereditary hemorrhagic telangiectasia (HHT) is a rare condition in which fragile vascular walls lead to increased risks of bleeding, cerebral abscesses, arteriovenous malformations, anemia, and thrombosis. To date, no protocol has been established...

Jun 24th, 2022 - Background: Olfactory neuroblastoma (ONB), also known as esthesioneuroblastoma, is a malignant tumor of the nasal cavity believed to arise from the olfactory epithelium. ONB is rare, with a reported incidence of 0.4 per million (approximately 300 ...

Jun 23rd, 2022 - History The development of myelodysplastic syndrome (MDS) may be preceded by a few years by an unexplained macrocytic anemia with no evidence of megaloblastic anemia and a mild thrombocytopenia or neutropenia. Clinical symptoms that should prompt ...

Jan 8th, 2020 - Nosebleed, also known as epistaxis, is a common problem that occurs at some point in at least 60% of people in the United States. While the majority of nosebleeds are limited in severity and duration, about 6% of people who experience nosebleeds w...

Jun 24th, 2022 - Background: Olfactory neuroblastoma (ONB), also known as esthesioneuroblastoma, is a malignant tumor of the nasal cavity believed to arise from the olfactory epithelium. ONB is rare, with a reported incidence of 0.4 per million (approximately 300 ...

Jun 22nd, 2022 - The safest and most effective post-operative pain control regimen after functional endoscopic sinus surgery (FESS) has been the subject of persistent debate and research for many years. The main reasons for this debate is due to two factors: 1) en...

Jun 14th, 2022 - Hereditary Hemorrhagic Telangiectasia (HHT) is a rare systemic autosomal dominantly inherited disorder of angiogenesis. Its major feature is the occurrence in 90% of patients of spontaneous and recurrent epistaxis responsible for iron deficiency a...

Jun 2nd, 2022 - The most common symptom of the hereditary hemorrhagic telangiectasia (HHT) disease is epistaxis. HHT is characterized by vascular (blood vessel) malformations, of the skin and mucus membranes of the nose (telangiectasia), gastrointestinal track, b...

May 31st, 2022 - The patients were routinely monitored in the operating room in accordance with the standard protocol for elective surgeries, and the preoperative findings (blood pressure, oxygen saturation, cardiac rhythm, peak heart rate) were recorded. The deci...

May 10th, 2022 - Nasopharyngeal carcinoma (NPC) differs from other head and neck (H&N) cancers in its epidemiology and treatment. Unlike other H&N cancers, NPC has a distinct geographical distribution with a much higher incidence in endemic areas, such as southern.

Apr 29th, 2022 - The combination of ceralasertib (AZD6738) and acalabrutinib (Calquence) showed preliminary clinical activity with acceptable tolerability in patients with high-risk, relapsed/refractory chronic lymphocytic leukemia (CLL), according to data from a ...

Mar 3rd, 2022 - The FDA has granted a fast track designation to the BCMA-targeting Tri-specific T-cell Activating Construct (TriTAC), HPN217, for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who have previously re...

Feb 3rd, 2022 - To the Editor: MYH9-related disorder is an autosomal-dominant disorder characterized by macrothrombocytopenia and neutrophil inclusions secondary to defective myosin-9. 1 We describe a case of lower leg hyperpigmentation secondary to hemosiderin de.

Jan 28th, 2022 - Treatment of patients with metastatic cervical cancer remains challenging—the 5-year overall survival (OS) rate is just 17%.1 Whereas many other solid tumors have seen a plethora of FDA approvals of clinically meaningful treatments, there has been...